Format

Send to

Choose Destination
Mol Immunol. 2015 Oct;67(2 Pt A):117-30. doi: 10.1016/j.molimm.2015.01.028. Epub 2015 Feb 17.

Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics.

Author information

1
Genmab, Utrecht, The Netherlands.
2
Genmab, Utrecht, The Netherlands; Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: P.Parren@genmab.com.

Abstract

Complement is recognized as a key player in a wide range of normal as well as disease-related immune, developmental and homeostatic processes. Knowledge of complement components, structures, interactions, and cross-talk with other biological systems continues to grow and this leads to novel treatments for cancer, infectious, autoimmune- or age-related diseases as well as for preventing transplantation rejection. Antibodies are superbly suited to be developed into therapeutics with appropriate complement stimulatory or inhibitory activity. Here we review the design, development and future of antibody-based drugs that enhance or dampen the complement system.

KEYWORDS:

Antibody; Antibody engineering; Cancer; Complement; Immunology; Therapy

PMID:
25697848
DOI:
10.1016/j.molimm.2015.01.028
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center